Cathie Wood's Ark Invest recently executed several notable trades, demonstrating a continued focus on disruptive innovation. The firm significantly increased its exposure to the cryptocurrency sector through investments in Bullish, a platform supported by Peter Thiel, and expanded its position in Robinhood Markets Inc. Concurrently, Ark divested a portion of its stake in Tempus AI Inc., a leader in AI-driven precision medicine. These portfolio rebalances underscore Ark's strategic vision, targeting companies at the forefront of technological advancement and market transformation.
On Tuesday, Ark Invest, under the leadership of Cathie Wood, made a substantial investment in Bullish, acquiring 356,346 shares for approximately $21.2 million. This move followed Bullish's impressive initial public offering, where its shares surged to $90.45, significantly above the $37 IPO price, briefly pushing its market capitalization beyond $16 billion. This recent acquisition adds to Ark's existing significant investment in Bullish, which competes directly with major cryptocurrency exchanges like Coinbase by facilitating trades in digital assets such as Bitcoin and Ethereum.
In another key transaction, Ark's ARK Innovation ETF (ARKK) purchased 150,908 shares of Robinhood, valued at about $16.2 million. This investment builds on Ark's previous acquisition of 123,336 Robinhood shares, worth approximately $14.2 million, which occurred as the trading platform formulated its 'Apocalypse Squad' strategy, signaling its resilience and strategic planning.
Conversely, Ark Invest reduced its holdings in Tempus AI, selling 113,952 shares from its ARKK ETF, equating to roughly $8.3 million. Tempus AI, a prominent entity in AI-driven precision medicine, recently announced strong financial results for the second quarter of 2025, with revenues increasing by 89.6% year-over-year to $314.64 million, surpassing analyst expectations. Despite the sale, Tempus AI remains a significant component of the ARKK portfolio and has been a major contributor to the fund's rally in 2025, with its stock price appreciating by 124% year-to-date. This growth is attributed to the tangible applications of artificial intelligence, robotics, and gene sequencing technologies.
Beyond these primary transactions, Ark Invest engaged in several other trades. The ARK Genomic Revolution Multi-Sector ETF (ARKG) and ARKK both acquired shares in Beam Therapeutics Inc. (BEAM), with ARKG buying 30,610 shares and ARKK adding 509,618 shares. Additionally, ARKK and ARKG collectively purchased 215,146 and 8,657 shares of CRISPR Therapeutics AG (CRSP), respectively. On the divestment side, Ark's ARK Web x.0 ETF (ARKW) sold 218,031 shares of Genius Sports Ltd (GENI), and both ARKK and ARK Autonomous Technology & Robotics ETF (ARKQ) reduced their positions in Deere & Co. (DE), selling 1,775 and 4,080 shares, respectively. Ark Space Exploration & Innovation ETF (ARKX) also made an acquisition, purchasing 2,261 shares of L3Harris Technologies Inc. (LHX).
The recent trading actions by Cathie Wood's Ark Invest reflect a dynamic approach to portfolio management, emphasizing high-growth, innovation-driven companies. The firm's substantial investments in crypto-related ventures like Bullish and trading platforms such as Robinhood, coupled with strategic adjustments in AI and biotech holdings like Tempus AI, signify a commitment to sectors poised for future expansion. These decisions are rooted in a belief in the transformative power of emerging technologies, aiming to capitalize on long-term disruptive trends across various industries.